Kapps v. Biosense Webster, Inc.’s Empirical Analysis
2011
Citation profile
5 district · 1 state decisions
Relationships
Applies 21 U.S.C. § 301 (Animal Drug Amendments of 1968) · 21 U.S.C. § 360C (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360E (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360K (Federal Food, Drug, and Cosmetic Act)
Relies on Anderson v. Liberty Lobby, Inc. · Daubert v. Merrell Dow Pharmaceuticals, Inc. · General Electric Co. v. Joiner · Buckman Company V.' Legal Committee · Riegel v. Medtronic, Inc.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 7 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“A plaintiff cannot prevail in a design-defect case simply by arguing, in the abstract, that a product is defectively designed. Instead, the plaintiff must explain why, under the reasonable-care balancing test, the world would be a better place if the product were either designed differently or taken off the market.”
1 later decision quote this exact passage · from the majority“(1) [PEI] had a duty to warn; (2) [PEI] breached that duty by providing an inadequate warning (or no warning at all); and (3) [PEI's] inadequate (or nonexistent) warning caused [Green Plains'] damages.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.